By Dr. Bernard W. TaylorTexas Oncology - Longview Cancer Center The American Cancer Society’s 2022 Cancer Facts and Figures report estimates that nearly 270,000 men will be diagnosed with prostate cancer this year. This represents nearly 50% more than the number of...
Revenue Increased 19% Year-Over-Year Prostate Brachytherapy Revenue Increased 13% Year-Over-Year RICHLAND, WASHINGTON – February 8, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced its...
Conference Call is Tuesday, February 8, 2022 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – January 26, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call...
By CEO Lori Woods This is my first blog post, and it comes during a year that has changed how we communicate, how we work, and virtually every aspect of our lives. COVID-19 has challenged us and changed us. We hope for better days ahead even as we face the reality of...
Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed...
To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page. ...
Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON –October 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout...
RICHLAND, WASHINGTON – September 28, 2021 – The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131...
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options...
Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body,...
To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page. [pdf-embedder...